Drug Trial Radar · NCT00282828
Improving Treatment Outcomes in Pharmacotherapy of Generalized Social Anxiety Disorder
Last checked: Nov 20, 2026Latest source record: Oct 14, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
397
Actual
Start
Mar 2006
Primary completion
Dec 2011
Study completion Dec 2011
Sponsor
- Lead sponsor
- Massachusetts General HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Institute of Mental Health (NIMH)
- First posted
- Jan 27, 2006
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will compare the effectiveness of either adding clonazepam or placebo to standard treatment or switching to venlafaxine in treating generalized social anxiety disorder in individuals who have not responded to treatment with sertraline.
Conditions
- Social Phobia
Interventions
SertralineDrug
VenlafaxineDrug
PlaceboDrug
ClonazepamDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rates of Remission (LSAS≤30) After 12 Weeks of Randomized Treatment During Phase II, Among Phase I Non-respondersTime frame: Measured at Week 22 (Endpoint)
Locations
3 sites in 2 countries. Site status is shown where the registry gives one.
University of California San Diego
La Jolla, California
Center for Anxiety and Traumatic Stress Disorders
Boston, Massachusetts
McMaster University Medical Centre Anxiety Disorders Clinic
Hamilton, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.